Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS 56 Revenue per Share is CHF17.59 as of Jun. 2026. GuruFocus rates XSWX:ZTS with a GF Score™ of 56/100 and a GF Value™ of CHF147.84 (Significantly Undervalued). Among 903 Drug Manufacturers companies, Zoetis ranks better than 63.9% on this metric.
Zoetis's revenue per share for the
three
months ended in Jun. 2026 was CHF4.72.
Zoetis's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was CHF17.59.
Good Sign:
Zoetis Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue Per Share Growth Rate of Zoetis was 6.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 7.50% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 8.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 9.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Zoetis's Revenue per Share or its related term are showing as below:
XSWX:ZTS'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 2.5 Med: 7.85 Max: 14.8
Current: 7.5
During the past 13 years, Zoetis's highest 3-Year average Revenue Per Share Growth Rate was 14.80% per year. The lowest was 2.50% per year. And the median was 7.85% per year.
XSWX:ZTS's 3-Year Revenue Growth Rate is ranked better than 63.9% of 903
companies
in the Drug Manufacturers industry
Industry Median: 3.8
vs XSWX:ZTS: 7.50
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Zoetis Revenue per Share Related Terms
Zoetis Revenue per Share Historical Data
* Premium members only.
The historical data trend for Zoetis's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZTS vs UTHR, VTRS, NBIX: Revenue per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zoetis's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Zoetis's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF17.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (XSWX:ZTS) has a Revenue per Share of CHF17.59 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Zoetis and its competitors. According to the industry distribution chart, Zoetis ranks #326 out of 903 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is Zoetis' Revenue per Share too high?
Zoetis' current Revenue per Share is CHF17.59. Based on the distribution chart, Zoetis ranks #326 out of 903 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zoetis has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Revenue per Share compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #326 out of 903 companies for Revenue per Share. This puts Zoetis in the upper half of its industry. The industry median Revenue per Share is 3.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.80, based on 903 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current Revenue per Share is CHF17.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF147.84, compared to a current price of CHF61.26 — trading 58.6% below its estimated fair value. The current Revenue per Share is CHF17.59. Zoetis' overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current Revenue per Share is CHF17.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.26 is trading 58.6% below its estimated GF Value™ of CHF147.84.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
Revenue per Share: CHF17.59
GF Value™: CHF147.84 vs. price of CHF61.26 (58.6% below fair value)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
56GF Score
Get the complete analysis for XSWX:ZTS
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
